| Status: Superseded | |
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED DECEMBER 2022. Refer to TA866 Regorafenib for previously treated metastatic colorectal cancer for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. |
|
Medicine details |
|
| Medicine name | regorafenib (Stivarga®) |
| Formulation | 40 mg film-coated tablet |
| Reference number | 740 |
| Indication | For the treatment of adult patients with metastatic colorectal cancer who have been previously treated with, or are not considered candidates for, available therapies. These include fluoropyrimidine-based chemotherapy, an anti-vascular-endothelial-growth-factor therapy and an anti-epidermal-growth-factor-receptor therapy. |
| Company | Bayer Healthcare Pharmaceuticals |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Superseded |
| Date of issue | 23/12/2022 |
| NICE guidance | TA866 Regorafenib for previously treated metastatic colorectal cancer |